Research Article |
Corresponding author: Ali Salama ( belarabi99@hotmail.com ) Academic editor: Plamen Peikov
© 2022 Ali Salama.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Salama A (2022) The development of a novel ultrashort antimicrobial peptide nanoparticles with potent antimicrobial effect. Pharmacia 69(1): 255-260. https://doi.org/10.3897/pharmacia.69.e81954
|
Conventional antibiotics are facing significant microbial resistance, which has recently reached previously unnoticed critical levels. As a result of this situation, a large proportion of antimicrobial agents currently used in the clinic have significantly reduced therapeutic potential. Antimicrobial peptides (AMPs) may offer the medical community an alternative strategy to traditional antibiotics in the fight against microbial resistance. Current research efforts are focused on developing technologies that may reduce AMP toxicity while retaining their potent antimicrobial activity and possibly improving their delivery. The ionotropic gelation method was used to encapsulate a novel in-house designed potent ultrashort antimicrobial peptide (USAMP) into chitosan-based nanoparticles (CS-NPs) in this study. WRWRWR -CS-NPs were tested for antibacterial kinetics against two strains of Staphylococcus aureus for four days, and the developed WRWRWR -CS-NPs showed a 3-log decrease in the number of colonies when compared to CS-NP and a 5-log decrease when compared to control bacteria. Loaded WRWRWR into CS-NPs could represent an innovative approach to develop delivery systems based on NPs technology for achieving potent antimicrobial effects against multi-drug resistant and biofilm forming bacteria with negligible systemic toxicity and reduced synthetic costs that are obstructing the clinical development of AMPs generally.
antibiotics, peptides, nanoparticles, chitosan, MRSA
Bacterial resistance to conventional antibiotics has increased significantly in recent decades, owing to massive overuse and misuse of antibiotics, which was triggered and facilitated by the medical community (
Because of these constraints, the majority of current research efforts are focused on improving AMPs stability and reducing systemic toxicity. In this regard, the encapsulation of antimicrobial peptides by nanocarriers may represent an innovative approach to overcoming some of the issues associated with the limited clinical use of AMPs (
Chitosan (CS) is a high molecular weight biodegradable and biocompatible poly cationic polysaccharide (
Medium molecular weight Chitosan (Mw 108 kDa) with deacetylation ~92% and sodium tripolyphosphate TPP were employed in all experiments (Sigma–Aldrich. USA).
The antimicrobial peptide employed in the present study is the novel ultrashort cationic antimicrobial peptides (USAMP) with six amino acid WRWRWR. The peptide was designed in house and has no similar to any other peptide deposited in official protein databases. The WRWRWR was obtained from (GL Biochem Ltd., Shanghai, China).
Acetic acid was purchased from Prolabo, France. Micro BCA Assay Kit was purchased from Thermo Scientific, USA. Mueller Hinton Agar was obtained from (Scharlap, S.L, Spain). Phosphate buffer saline (PBS) was purchased from Oxoid, England. Mammalian Vero cell line was purchased from (ATCC, USA). tryptone soy broth (TSB) (EcoBio, Hungary). MTT Formazan was purchased from Santa Cruz biotechnology, USA.
Water Bath (Germany) , Elisa Plate Reader (Biotech USA) , Incubator (USA) , Hot plate (USA) , Liquid Chromatography-Mass Spectrometry (LC-MS) (Germany), Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) (Germany) and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) (China).
The following bacterial strains were obtained from the American type tissue culture collection (ATCC) for the determination and testing of the WRWRWR - CS-NP: The control strain was Staphylococcus aureus (ATCC 29213). Staphylococcus aureus (ATCC BAA-41) was also used in the study, which was clinically isolated in a hospital in New York City in 1994 (MRSA).
WRWRWR was synthesized using the solid-phase method and Fmoc chemistry, and it was purified using reverse phase high-performance liquid chromatography with an acetonitrile / H2O-TFA gradient. We used arginine (R) to display the positive charge of the peptide and use tryptophan (W) to increase the hydrophobicity of the peptide. The peptide’s identity was confirmed using ESI-MS mass spectrometry (GL Biochem Ltd., Shanghai, China).
The CS-NPs and WRWRWR -CS-NPs were prepared using the simple ionic gelation method described previously, with minor modifications (
The hydrodynamic radius of NPs was measured using dynamic light scattering (DLS). At 20 degrees Celsius, 1 ml (0.5 mg/ml) of each sample was added to disposable polystyrene cuvettes. The developed NPs’ zeta potential (ZP) was measured using a zetasizer ZS (Malvern, UK) at 25 °C in 10 mM phosphate buffer saline PBS, pH 7.4. The samples (0.5 mg/ml) were filtered through a 0.45 m filter unit before being injected into folded capillary cells.
Following WRWRWR -CS-NPs purification, the amount of WRWRWR found in the supernatant was measured at 562 nm using the Micro BCATM protein assay according to the manufacturer’s recommendations (Thermo Fisher, USA).
Purified WRWRWR -loaded CS-NPs were redispersed in 1 ml of PBS, pH 7.4, and stirred in a shaking incubator at 37 °C. At various time intervals, the sample was centrifuged at 2980 g for 2 hours at 4 °C, and 1 ml of fresh PBS medium was added to replace the collected supernatant. The amount of peptide released from the nanoparticle was determined using the Micro BCA protein assay (
Yellow tetrazolium (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) MTT is reduced to purple formazan inside the cell by reductase enzymes. As a result, only metabolically active cells can catalyze this reaction and generate the purple formazan crystals. Although these purple crystals are insoluble in water, they can be dissolved in Dimethyl Sulfoxide (DMSO). These crystals’ generated color can be measured spectrophotometrically at 550 nm wavelength. Cells were seeded in 5 × 103 cells per well in a flat-bottomed 96-well plate for the MTT assay, and the plates were incubated for 18–24 h at 37 °C supplemented by 5% CO2 for the attached on the bottom of the plates. The following day, different concentrations of WRWRWR -CS-NPs were suspended in RPMI as the dissolving media and added to the cells in the plates (2.5, 5, and 10 mg/ml, loaded with 255, 510, and 1020 g/ml of WRWRWR, respectively). As a control, the untreated medium is used. The plates were incubated for 24 hours at 37 °C with 5% CO2 added. After 24 hours, 20 l of the MTT solution (2.5 mg/ml) was added to each well, and the plates were incubated for 2–5 hours at 37 °C, 5% CO2. The well content was removed after this incubation period (ensure that all the solution in the wells is removed). Each well received 100 l of DMSO, which was thoroughly mixed by pipetting to dissolve the Formazan crystals at the bottom of the wells until a clear purple color was obtained. The plates were then placed on an Elisa Microplate Reader (BioTek, USA) and the absorbance at = 550 nm was measured (
We use three units of tryptophane and three unites of arginine amion acid to made our hexapetide after that we combined it with 1-(2, 6-difluorobenzyl)-1H-1, 2, 3-triazole-4-carboxylic acid to increase its efficacy, the structure of the peptide shown in Fig.
The CS-NPs and WRWRWR -CS-NPs were made using a simple ionic gelation method. The average diameter of the formulated NPs was determined using dynamic light scattering. The analysis clearly showed that WRWRWR loading increased the average diameter of the NPs. The average diameter of the CS-NP increased from 110.27 0.5 to 118.13 1.01 for the WRWRWR-CS-NP (Table
The encapsulation efficacy and loading capacity of WRWRWR into CS-NPs were measured at 562 nm using the Micro BCATM protein assay, as shown in Fig.
The characterization of CS-NPs and WRWRWR -CS-NPs: Encapsulation Efficacy (EE), Loading Capacity (L), and formulations yield (Yield).
Formulation | EE (% ± SD) | L (% ± SD) | Yield (% ± SD) |
---|---|---|---|
CS-NP | - | - | 40.66 ± 1.25 |
WRWRWR -CS-NP | 53.23 ± 1.52 | 10.11 ± 0.2 | 40.61 ± 0.55 |
For 14 days, the WRWRWR release kinetics from WRWRWR -CS-NPs were studied in PBS at pH 7.4. (Fig.
Preparatory experiments were carried out in order to optimize the antibacterial activity of CS-NPs and WRWRWR -CS-NPs over long periods of time. The optimal concentration of TSB in PBS for sustaining bacterial growth for four days has been reported to be 1.25 percent (v/v). Furthermore, it was discovered that 5 mg/ml of RBRBR-CS-NPs was optimal for determining the formula’s activity over a 4-day period. The 5 mg/ml of WRWRWR -CS-NPs displayed significant antimicrobial activity against all the studied bacterial strains. The encapsulated WRWRWR -NP was able to inhibit the growth of all the studied bacterial strains employed in this study. The antibacterial activity of WRWRWR -CS-NPs was assessed by measuring the cell viability, which was expressed as log10 CFU/ml for each tested bacterial strain. Then it was compared to that 5 mg/ml of CS-NPs and to the control (Table
Antibacterial activity of WRWRWR -CS-NPs as compared to CS-NPs and Control against MRSA S. aureus (ATCC 33591), (ATCC 43300), and clinically isolated MRSA S. aureus (ATCC BAA-41). (± SD).
ATCC | Log CFU/ml 5 mg/ml WRWRWR -CS-NP | Log CFU/ml 5 mg/ml CS-NP | Log CFU/ml Positive control |
---|---|---|---|
29213 | 2.51 ± 0.045 | 5.96 ± 0.052 | 10.79 ± 0.017 |
BA-41 | 3.11 ± 0.043 | 7.06 ± 0.026 | 9.02 ± 0.012 |
The developed NP successfully reduced the toxicity of the same amount of loaded WRWRWR against normal cell lines. The results of the cytotoxicity assay revealed that RBRBR has an IC50 value of 187.2 g/ml (Fig.
The current work aims to take advantage of NP advancement and USAMPs by encapsulating the in-house designed novel USAMP named WRWRWR into CS-NPs to determine if the incorporation of WRWRWR into CS-NPs might retain the peptide’s antimicrobial activity while reducing its toxicity. When we synthesis the peptide we take into consideration the balance between the hydrophilic and hydrophobic part, so we use arginine (R) to give the peptide the optimum charge (+3) and we use tryptophan to give the hydrophobicity of the peptide , also we comined our peptide with 1-(2, 6-difluorobenzyl)-1H-1, 2, 3-triazole-4-carboxylic acid to increase the antimicrobial activity of the peptide due to the good activity of triazole compound against different type of bacteria.
Ionic gelation was used to prepare the formulated WRWRWR -CS-NP, which was then tested for physio-chemical characterization, release kinetics, bacterial susceptibility, and cytotoxicity. Because of the positive charge of CS in acidic media, electrostatic repulsion with the cationic WRWRWR is possible (
The advancement of nanotechnology was used in this study to create an efficient drug delivering system that is an innovative therapeutic model based on CS-NPs loaded with novel USAMP to treat microbial resistance. The requirements characterizations of the nanosystem are excellent. The antimicrobial activity of WRWRWR -loaded CS-NPs in this study indicates that they have potent selective and long-acting activities against a wide range of Gram-positive bacteria, including clinical isolates of resistant strains. The MTT assay results show that WRWRWR loaded into nanocarriers has minimal toxicity against human erythrocytes and normal cell lines while displaying significant selectivity against microbial cells when compared to free WRWRWR. The encapsulation of AMPs in nanoparticles would be a novel and promising approach to AMP delivery.
The author is grateful to the Middle East University (MEU), Amman, Jordan, for the financial support granted to cover the publication fee of this research article.